A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
|Videos|August 31, 2020
What quality registry data reveal about urethral stricture treatment
Andrew J. Cohen, MD, discusses a recent study evaluating treatment of urethral stricture disease in the US.
Advertisement
Andrew J. Cohen, MD, assistant professor of urology at Johns Hopkins University, regarding a recently published study in Urology titled “Significant Management Variability of Urethral stricture Disease in United States: Data from the AUA Quality (AQUA) Registry.” Cohen says the study provides “a small glimpse into the truly enormous research potential of the AUA Quality Registry.”
Advertisement
Related to this article
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Advertisement
Advertisement